updating my status
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
pfff why sell now when it was just .07
i slept in again, and what do ya know!? ha
reminds me of the lull in the candles at .013
congrats all
what kind of news are you expecting?
quite volitile this one is
A/H news anyone?
what a great day i'm having so far... slept in... FTCH moving up... found out yesterday one of my old jobs wants to hire me back... playing bejeweled blitz on facebook... rather carefree if you ask me
niceeeee
someone as in Mitch28?
i thought you can't make pre or post market trades on pinkies
how much you wanna bet those weren't "actually" A/H but held?
ugh... where's the fastforward button???
sweet UT!
this play looks good
zero percent
sweeeeeeeeet
where is the breakout line?
well why don't you post your all knowing perspective? damn near every indicator is flat and near zero/50
uhhhhh the chart
A/D & CMF sure are looking hot these days. everything else is nearly neutral
GJYEAH! greenage
here we go, the most tense 30 seconds of the day!
let me guess, holding back your order(s)? hopefully they hold back bids AND asks then!
this is such a STRUGGLE
i bet a MM picked them up... large trades like that i doubt retail got it but you never know.
are you serious? 117k???
yea, the price!
yea, the price!
hopefully good news tomorrow
aaaand back to "normal" again. lol.
wow spread filled
Cannabis Science Receives FDA Industry Guidelines for Mapping Out Its Initial Drugs Offerings for FDA Submission and Testing
2:35p ET July 28, 2009 (Market Wire)
Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to report that the FDA has provided the Company with documentation to assist the Company to review and plan its initial applications to get its first drug into formal testing.
Cannabis Science, Inc. President & CEO Dr. Robert Melamede stated, "After speaking directly with the FDA discussing our products and initiatives I was pleasantly surprised with the hands on approach they have with helping us map our path to get our products into testing. We have a ways to go, but I am very optimistic that we have an opportunity to have more than one product in testing and trials at the same time. We have an exciting new initiative we plan to announce shortly and I would like to thank our current and future shareholders for helping to make this happen."
Cannabis Science H1N1 Swine Flu Formulation:
We now know that the endocannabinoid system plays a critical role in maintaining human health. The human body produces Endocannabinoids on demand when they are needed. They help restore homeostasis (biochemical balance). The Cannabis plant produces Phytocannabinoids. When the human body has endocannabinoid deficiencies, it cannot effectively restore the healthy biochemical state needed to counter a particular illness. Phytocannabinoids from the Cannabis plant can replace the deficient endocannabinoid activity in the human body to restore a health-promoting level of cannabinoid activity. Cannabis Science will test its cannabis extract lozenge with FDA guidance and oversight to determine if it will reduce ARDS-associated deaths from both the Avian and Swine influenza infections.
H1N1 Swine Flu:
According to the CDC (http://www.cdc.gov/flu/avian/) the Avian flu (H5N1) has a 63% mortality rate. Unfortunately, the Swine flu, while causing death at a much lower rate than the Avian flu, appears to also result in death via a similar mechanism. The common cause of death with these strains is organ failure, especially as seen in the lungs with the development of Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company's approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc. Dr. Robert J. Melamede President & CEO Email Contact www.cannabisscience.com 1-888-889-0888 Catalyst Xchange Corp. Corporate Communications Donald Shaxon 1-866-216-3269 Brokers and Analysts: Wall Street International John Campo 1-410-236-8200
SOURCE: Cannabis Science, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=520CCE389E02B502 http://www.cannabisscience.com
this sure is an interesting little company
July 29, 2009 Conference calls:
LTFD
PHLI
FSRV
CTGX
i did a quick search, will look for more tonight
a lot of people say that on a lot of stocks but it actually applies here
still waiting on this one...
if you want in right NOW you'll have to bid .052-.055
already $5000+ profit